AOD-9604 Endurance Athletes Protocol: Dosing, Timing, and What the Evidence Actually Shows

What Is AOD-9604 and Why Do Endurance Athletes Use It?

AOD-9604 is a 16-amino-acid synthetic peptide corresponding to the C-terminal region of human growth hormone. Researchers at Monash University isolated this fragment specifically because it reproduces hGH's lipolytic activity without triggering the receptor-mediated IGF-1 axis that causes insulin resistance, acromegalic side effects, and anabolic signaling. Endurance athletes, particularly marathoners, cyclists, and triathletes, have adopted it primarily to reduce excess adipose mass without compromising muscle protein or spiking blood glucose during periodized training blocks.

Why Fragment 176 to 191 Specifically?

The full hGH molecule binds two receptor sites. Site 1 drives growth and IGF-1 secretion; site 2, located in the 176 to 191 region, drives lipolysis through a separate downstream pathway involving beta-3 adrenergic receptors and adipocyte AMPK signaling [1]. Isolating fragment 176 to 191 preserves lipolytic activity while leaving IGF-1 largely unaffected. A preclinical study published in the Journal of Endocrinology demonstrated that obese mice treated with AOD-9604 lost significantly more fat mass than controls without the hyperglycemia seen with intact hGH administration [2].

How Endurance Demands Create a Use Case

Runners and cyclists logging 12 to 20 hours per week often carry sub-optimal body-fat percentages, yet caloric restriction sufficient to drop fat also impairs glycogen resynthesis and raises cortisol. An agent that shifts the lipolytic dial without compromising carbohydrate metabolism has theoretical appeal. The mechanistic argument is sound. The human clinical data, however, are modest in sample size and come from obese rather than athletic populations, so practitioners must apply the evidence carefully.

Evidence Base: What the Clinical Trials Actually Show

Understanding the evidence hierarchy for AOD-9604 is non-negotiable before structuring any protocol. The compound has three published human clinical phases, all conducted by Metabolic Pharmaceuticals Ltd. And all focused on obesity, not athletic performance.

Phase IIa: Dose-Finding in Obese Adults

A randomized, double-blind, placebo-controlled trial (N=300) tested oral AOD-9604 at doses of 1 mg, 5 mg, 10 mg, and 30 mg over 12 weeks in overweight adults. At the 1 mg oral dose, the trial reported statistically significant fat loss compared to placebo, with no change in fasting insulin, glucose, or IGF-1 [3]. Oral bioavailability of peptides is notoriously low, so the effective subcutaneous equivalent dose is substantially less than 1 mg oral.

Phase IIb: Extended Efficacy

A subsequent 24-week Phase IIb trial (N=536) showed modest but statistically significant reductions in body fat percentage in the active arm versus placebo [4]. The effect size was smaller than anticipated, which contributed to the compound failing to advance through Phase III as an oral obesity drug. Subcutaneous delivery was not formally studied in the key Phase III setting.

Animal and Mechanistic Data

Multiple rodent studies confirm lipolytic efficacy via subcutaneous injection at doses translating to approximately 2 to 10 mcg/kg in humans [1, 2]. These animal data inform the practitioner-derived dosing ranges in use today, since human subcutaneous RCTs do not exist. Evidence level for subcutaneous protocols in athletes is therefore: mechanistic animal data plus observational practitioner experience. That distinction matters for informed consent.

The FDA has not approved AOD-9604 for any indication [5]. Prescribers and patients must understand this before use.

Structured Protocol for Endurance Athletes

The following protocol synthesizes the published clinical pharmacology with practitioner-reported experience. Evidence level for each component is labeled explicitly.

Dose

• Starting dose: 300 mcg subcutaneously per injection (Evidence level: mechanistic animal data extrapolated to human; practitioner consensus)
• Maintenance dose: 300 to 500 mcg subcutaneously per injection (Evidence level: same)
• Maximum studied oral equivalent: approximately 1 mg oral, translating to a lower subcutaneous figure given first-pass elimination differences [3]

Do not exceed 500 mcg per injection without direct physician supervision and baseline labs in hand. Doses above this range have no supporting human safety data in athletic populations.

Route and Injection Technique

Subcutaneous injection into the periumbilical fat, anterior thigh, or lateral hip is the standard approach. Use a 29- or 31-gauge, 5/16-inch (8 mm) insulin syringe. Rotate sites to avoid lipodystrophy. Reconstitute lyophilized powder with bacteriostatic water at a concentration that makes dose measurement simple, typically 2 mg reconstituted in 2 mL bacteriostatic water (yielding 1,000 mcg per mL, or 0.3 mL per 300 mcg dose).

Refrigerate reconstituted peptide at 2 to 8°C. Discard after 28 days.

Timing

The Phase IIa oral data and the animal subcutaneous data both suggest maximal lipolytic effect occurs in a fasted state when insulin is low [3]. For endurance athletes, two timing windows are practical:

1. Morning fasted, 30 to 60 minutes before fasted steady-state cardio (e.g., a zone-2 run before breakfast). Low ambient insulin during this window may potentiate beta-3 adrenergic receptor engagement.
2. Pre-sleep, 2 to 3 hours after the last meal, when insulin has returned toward baseline and endogenous growth hormone pulsatility is rising.

Do not inject immediately before a carbohydrate-heavy meal. Elevated insulin may blunt lipolytic signaling. This timing principle is mechanistically derived, not directly tested in athletes [1].

Frequency

Once daily. The peptide's plasma half-life is short (estimated <30 minutes for the fragment based on structural analogy to hGH C-terminal peptides), but downstream receptor signaling persists for hours [2]. Twice-daily dosing is sometimes reported anecdotally but lacks any supporting clinical trial data and doubles cost and injection burden without proven additional benefit.

Cycle Length

| Phase | Duration | Rationale | |---|---|---| | Loading / ramp | Weeks 1 to 2 at 300 mcg | Assess tolerance, watch glucose | | Maintenance | Weeks 3 to 12 at 300 to 500 mcg | Primary effect window | | Optional extension | Weeks 13 to 16 | Only if labs remain normal | | Off-cycle | 4 to 8 weeks minimum | Receptor sensitivity; no tachyphylaxis data in humans |

A 12-week cycle aligns with the primary Phase IIa and Phase IIb trial durations [3, 4]. Extended use beyond 16 weeks has no published human safety data.

Stacking Considerations for Endurance Athletes

Many practitioners combine AOD-9604 with other peptides. The most common pairings in endurance contexts are:

• BPC-157 (300 to 500 mcg subcutaneously at injury site or systemically) for tendon and connective tissue recovery. Animal data support accelerated tendon repair [6].
• TB-500 (Thymosin Beta-4) at 2 to 5 mg per week subcutaneously for systemic tissue repair and angiogenesis promotion in preclinical models [7].
• CJC-1295/Ipamorelin to augment endogenous GH pulsatility if the athlete also needs recovery acceleration and sleep quality improvement.

Stacking increases complexity, cost, compound interactions, and regulatory risk. Discuss each addition separately with your physician. Do not combine AOD-9604 with exogenous insulin or IGF-1 analogs without direct endocrinologist involvement.

Expected Timeline of Outcomes

Realistic outcome expectations prevent abandonment of a protocol that is working or continuation of one that is not.

Body Composition

In the Phase IIb 24-week trial, measurable fat-mass reduction reached statistical significance by week 8 to 12 in the active arm [4]. Athletes at lower baseline body-fat percentages (10 to 18%) may see slower absolute changes than the obese trial participants. A DEXA scan at baseline and at 8 weeks provides objective data. Do not rely solely on scale weight, which fluctuates with glycogen and hydration.

Recovery Perception

No published trial has measured recovery time-to-readiness in athletes using AOD-9604. Anecdotal reports from triathlon and ultramarathon communities describe reduced post-long-run soreness within 2 to 4 weeks, but this is observational and subject to placebo effect. Tracking perceived recovery via validated tools such as the Total Quality of Recovery (TQR) scale gives at least semi-objective data over a protocol cycle [8].

Performance Metrics

AOD-9604 is not a performance-enhancing compound in the direct sense. It does not increase VO2 max, improve lactate threshold, or drive erythropoiesis. Any performance benefit is indirect: if a runner drops 2 to 3 kg of fat mass with preserved VO2 max, running economy improves. A 1% reduction in body mass improves running economy by approximately 1% in trained athletes [9]. Set expectations accordingly.

Monitoring Labs and Safety

Baseline Panel (Before Week 1)

• Fasting glucose and insulin
• HbA1c
• IGF-1 (to confirm AOD-9604 is not driving IGF-1 elevation)
• Complete metabolic panel
• Lipid panel
• Thyroid panel (TSH, free T4)
• CBC

8-Week Follow-Up Panel

Repeat fasting glucose, insulin, IGF-1, and HbA1c. The Phase IIa and IIb trials both confirmed no significant change in IGF-1 or insulin at the studied doses [3, 4]. If either marker rises meaningfully above baseline, pause the protocol and reassess.

Safety Profile from Clinical Trials

The published Phase II trials reported no serious adverse events attributable to AOD-9604 at the studied doses. The most commonly noted findings were mild injection-site reactions (redness, transient swelling) and occasional headache in the first week [3]. No carcinogenicity or genotoxicity signal emerged in the 90-day rodent studies submitted with the clinical data package.

The American Association of Clinical Endocrinology (AACE) guidelines on growth hormone therapy caution that any GH-axis-active compound requires monitoring for glucose dysregulation and IGF-1 elevation [10]. Those principles apply here despite AOD-9604's favorable preclinical profile.

Anti-Doping Alert

WADA prohibits AOD-9604 under Section S2 of the Prohibited List (Peptide Hormones, Growth Factors, Related Substances). Any athlete subject to anti-doping testing, including masters-age competitors in USATF, USA Cycling, and ITU/World Triathlon events, faces a potential positive test and suspension. Consult the Global DRO database and your sport federation before use [11].

Who Should Not Use AOD-9604

• Athletes under 18 years of age
• Anyone with active malignancy or personal/family history of GH-sensitive cancers
• Pregnant or breastfeeding athletes
• Athletes competing in WADA-governed events
• Anyone with uncontrolled diabetes (fasting glucose >126 mg/dL or HbA1c >6.5%) without endocrinologist co-management
• Anyone sourcing AOD-9604 without physician prescription and third-party-tested product (certificate of analysis confirming identity and purity)

Where HealthRX Fits Into This Protocol

Physician-supervised peptide protocols differ from self-directed experimentation in three ways: baseline labs establish a safety floor, compounding pharmacy sources are vetted for quality, and dose adjustments are guided by objective data rather than forum consensus. The HealthRX medical team uses a standardized intake panel that includes fasting glucose, IGF-1, and a full metabolic panel before any peptide is prescribed, with an 8-week re-check built into every initial protocol.

Based on intake data from endurance athletes seen through HealthRX, the most common reason athletes abandon an AOD-9604 protocol prematurely is unrealistic body-composition expectations in the first 4 weeks. DEXA-confirmed fat-mass change in trained athletes typically lags the scale and requires at least 8 weeks to be reliably detectable.